News Releases
  Events & Presentations
  Corporate Governance
      Documents & Charters
      Board of Directors
      Committee Composition
  SEC Filings
  Stock Information
      Historic Stock Lookup
      Investment Calculator
  Annual Reports
  Email Alerts

News Releases

All Releases
View Summary Optimer Pharmaceuticals Submits Fidaxomicin Marketing Authorization Application for the Treatment of Clostridium difficile Infection
Jul 29, 2010
PDF 12.8 KB
View Summary Optimer Pharmaceuticals to Present at August 2010 Investor Conferences
Jul 28, 2010
PDF 9.1 KB
View Summary Optimer Pharmaceuticals Receives Milestone Payment From Cempra for Next-Generation Macrolide Antibiotic
Jul 8, 2010
PDF 11.3 KB
View Summary Optimer Pharmaceuticals to Present at June 2010 Investor Conferences
Jun 1, 2010
PDF 9.2 KB
View Summary Optimer Pharmaceuticals and Biocon Limited Announce Manufacturing and Supply Agreement for Fidaxomicin
May 24, 2010
PDF 12.5 KB
View Summary Optimer Pharmaceuticals Reports First Quarter 2010 Financial Results
May 6, 2010
PDF 13.5 KB
View Summary Optimer Pharmaceuticals Appoints Pedro Lichtinger as President and CEO to Succeed Michael N. Chang, Ph.D., Who Will Serve as Chairman of the Board
May 6, 2010
PDF 11.3 KB
View Summary Data From Optimer's Second Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection (CDI) Featured in Oral Presentation at Digestive Disease Week
May 4, 2010
PDF 12.9 KB
View Summary Optimer Pharmaceuticals Announces Oral Presentation at Digestive Disease Week (DDW) Featuring Data From the Second Fidaxomicin Phase 3 Trial
Apr 22, 2010
PDF 8.5 KB
View Summary Positive Results from Optimer Pharmaceuticals' Second Phase 3 Study of Fidaxomicin for the Treatment of Clostridium difficile Infection (CDI) Presented at ECCMID
Apr 10, 2010
PDF 15.8 KB
View Summary Optimer Pharmaceuticals Announces Presentations of Data From the Fidaxomicin Phase 3 Trials at ECCMID
Apr 6, 2010
PDF 9.0 KB
View Summary Optimer Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Financial Results
Mar 11, 2010
PDF 17.8 KB
View Summary Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2009 Financial Results
Mar 3, 2010
PDF 9.1 KB
View Summary Optimer Pharmaceuticals, Inc. Announces Completion of Public Offering of Common Stock
Mar 1, 2010
PDF 7.8 KB
View Summary Optimer Pharmaceuticals to Present at the Cowen and Company 30th Annual Health Care Conference
Mar 1, 2010
PDF 8.7 KB
View Summary Optimer Pharmaceuticals, Inc. Announces Pricing of Public Offering of Common Stock
Feb 24, 2010
PDF 8.8 KB
View Summary Optimer Pharmaceuticals Announces Positive Results From Second Fidaxomicin Phase 3 Study in Patients With Clostridium Difficile Infection
Feb 4, 2010
PDF 17.1 KB
View Summary Optimer Pharmaceuticals to Present at the 28th Annual J.P. Morgan Healthcare Conference
Dec 16, 2009
PDF 8.7 KB
View Summary Optimer Pharmaceuticals Appoints Robert L. Zerbe, M.D. to its Board of Directors
Dec 3, 2009
PDF 10.3 KB
View Summary Optimer Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference
Nov 24, 2009
PDF 8.6 KB
Showing 1-20 of 115 Page: 1 2 3 ... 6  Next 20
Print Print page
Email Email page

Stock Quote
NASDAQ:OPTR
$9.19   - 0.16
Jul 29, 2010
3:59 PM ET
Quotes delayed at least 20 minutes.
Data provided by eSignal.


Home | About Us | Product Pipeline | Research & Development | Resources | News & Press | Investors | Careers | Contact Us
© Copyright 2010 Optimer Pharmaceuticals, Inc. Powered by BlueSwitch.